|Free Dividend Report|
|Stock Splits Calendar|
|BLPH Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|BLPH Message Board|
Bellerophon Therapeutics (BLPH) has 1 split in our BLPH split history database. The split for BLPH took place on February 10, 2020. This was a 1 for 15 reverse split, meaning for each 15 shares of BLPH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Bellerophon Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BLPH split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bellerophon Therapeutics shares, starting with a $10,000 purchase of BLPH, presented on a split-history-adjusted basis factoring in the complete BLPH split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-45.94%|
|About Bellerophon Therapeutics|
|Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products that address unmet medical needs in the treatment of cardiopulmonary diseases. Co.'s focus is the continued development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using its proprietary pulsatile nitric oxide delivery platform, INOpulse. Co.'s INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing its INOpulse for the treatment of patients with fibrotic interstitial lung disease at a risk for pulmonary hypertension. According to our BLPH split history records, Bellerophon Therapeutics has had 1 split.|
|BLPH Split History Table|
|02/10/2020||1 for 15|
|Healthcare Stock Splits|
|BLPH is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: BLPH shares outstanding history